kinetoplastid-selective proteasome inhibitor

oral antileishmanial in Ph. I in HV

From 3M cmpd antiprolif. screen + opt.

J. Med. Chem., Jul. 29, 2020

Novartis (GNF), San Diego, CA

LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks